Clinical Trials Logo

Relapsed CLL clinical trials

View clinical trials related to Relapsed CLL.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03639324 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

RIVe-CLL/SLL
Start date: October 2, 2020
Phase: Phase 1
Study type: Interventional

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab